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Abstract
In recent years, a group of tumors that have been designated "perivascular epithelioid cell tumors"
(PEComa) have been reported with increasing frequency from a wide variety of anatomic locations.
The uterus and retroperitoneum appear to be the most frequent sites of origin for these lesions.
PEComas belong to an identically named family of tumors comprised of conventional
angiomyolipomas, clear cell sugar tumors, lymphangiomyomatosis and clear cell myomelanocytic
tumor of the falciform ligament/ligament teres, and are also known as PEComa-NOS. This article
is a primer for clinicians on the most salient clinicopathologic features of uterine PEComas, as most
of the debate and discussion have taken place in the pathologic literature. The author appraises in
detail the current state of knowledge on PEComas of the uterus based on a review of published
data on the 44 previously reported cases, and comments on areas of controversy. The latter are
centered predominantly on the significant morphologic and immunophenotypic overlap that exists
between uterine PEComa and some smooth muscle tumors of the uterus. The clinicopathologic
features of cases reported as epithelioid smooth muscle tumors and cases reported as uterine
PEComas are compared and contrasted, and a practical approach to their reporting is proposed.
Background
In 1994, Bonetti et al [1] proposed the concept of a family
of tumors comprised of angiomyolipoma, clear cell sugar
tumors and lymphagioleiomyomatosis. The proposal was
based on observations that these 3 lesions shared a mor-
phologically and immunophenotypically distinctive cell
type which the authors had previously designated
"perivascular epithelioid cell" [2,3]. Cells that are proba-
bly synonymous with these perivascular epithelioid cells
(PECs) were first noted in renal angiomyolipomas by
Apitz in 1943 [4]. These cells lack a normal anatomic
homologue, have spindle to epithelioid shapes with clear
to eosinophilic cytoplasm, display a predilection for
perivascular arrangements, and display immunoreactivity
for melanocytic markers such as HMB-45, micropthalmia
transcription factor (miTF), Melan A, Mart-1, HMSA-1
and to a lesser extent, muscular markers such as actin and
desmin [5-15]. PECs are envisioned by the Bonetti group
as possessing a phenotypic plasticity wherein the cells
may assume a spindled appearance and be more likely to
be positive for muscular markers, an epithelioid appear-
ance associated with a higher frequency of immunoreac-
tivity for melanocytic markers, or various phenotypic
modulations in between [14,15]. Over the subsequent
one and a half decades, an increasing number of neo-
plasms putatively composed of PECs have been reported
from a wide variety of anatomic locations under a simi-
larly wide variety of appellations. The term PEComa was
introduced in 1996 by Zamboni et al to describe one such
case arising in the pancreas [16]. Perivascular epithelioid
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cell tumors received formal recognition in 2 monographs
published under the auspices of the World Health Organ-
ization (WHO) in 2002 and 2003. [10,17]. In the WHO
classification of soft tissue neoplasms [10], PEComa was
defined as "mesenchymal tumors composed of histologi-
cally and immunohistochemically distinctive perivascular
epithelioid cells", including angiomyolipoma, clear cell
sugar tumors, lymphagioleiomyomatosis, clear cell myo-
melanocytic tumor of the falciform ligament/ligament
teres and other unusual clear cell tumors at various loca-
tions [10]. Clear cell myomelanocytic tumor of the falci-
form ligament/ligament teres [18] is presently not
considered sufficiently distinctive and is now generally
included in the latter group of "unusual clear cell tumors"
at various locations. The designation PEComa-NOS
(perivascular epithelioid cell tumors-not otherwise speci-
fied) has been applied to these "unusual clear cell tumors"
to avoid applying the same designation – PEComa – to
the family of lesions as well as a constituent subset [5-8].
However, the unqualified "PEComa" designation is recog-
nized in the WHO monographs [10,17] and will be used
henceforth in this article to describe the aforementioned
constituent subset. PEComas display an overwhelming
female preponderance and appear to be anatomically
ubiquitous [5,11-15]. However, the uterus and retroperi-
toneum have emerged as the 2 most frequently reported
sites of origin for these neoplasms [5,7,8,12]. Notably,
most of the uterine cases were described within the past
decade [8]. The first uterine PEComa was described in
1992 [19], and 43 additional cases have subsequently
been reported in the English literature [5,13,20-41]. In
this article, the author evaluates the current state of
knowledge on PEComas of the uterus, with an emphasis
on controversial areas and their unclear relationship with
uterine smooth muscle neoplasia.
Uterine PEComas: clinical features
Clinical features of the 44 previously reported cases of
uterine PEComa are summarized in Table 1. These cases
include tumors reported as PEComa, perivascular epithe-
lioid cell tumor, abdominopelvic sarcoma, hyalinized
uterine mesenchymal neoplasms with HMB-45-positive
epithelioid cells, epithelioid angiomyolipoma [5,13,19-
41], and excludes cases reported as conventional angi-
omyolipoma, lipoleiomyomas and lymphangioleiomyo-
matosis of the uterus [42-49]. One case that was originally
reported as lymphangioleiomyomatosis [50], but which
was subsequently included in a series of PEComas [33], is
included. Only cases reported prior to January 31, 2008 in
the English literature are included.
Forty and four of these 44 cases arose in the uterine corpus
and uterine cervix respectively. The patients ranged in age
from 9 to 79 (mean 45). The presentations were wide and
varied, and included abnormal vaginal bleeding, abdom-
inopelvic pain, uterine rupture, and hemoperitoneum;
the tumors were incidental discoveries in several cases
[5,13,19-41]. The radiological appearances have been
similarly varied and appear to be largely dependent on the
biologic characteristics of the underlying tumors. They
may be small and homogeneous, simulating a benign
smooth muscle neoplasm or they may be large, lobulated
and heterogeneous masses [51]. Overall, neither the clin-
ical presentation nor radiologic appearance of uterine
PEComas is sufficiently distinctive to allow the diagnosis
to be suggested preoperatively.
Preliminary data is suggestive of a possible association
between uterine PEComa and the tuberous sclerosis com-
plex (TSC). TSC is an autosomal dominant syndrome, one
of the phacomatoses, that may be characterized by a wide
variety of neoplastic manifestations, including renal angi-
omyolipomas, lymphangioleiomyomatosis, cardiac rhab-
domyomas, subependymal giant cell astrocytoma as well
as several others [52]. Four (9.1%) of the 44 patients with
uterine PEComas also had the TSC [5,33,34]. Although
this rate of association is probably inflated due to the
selection bias associated with the reported cases, it is still
notably higher than any other neoplastic process of the
uterus, and suggests that patients with uterine PEComa be
briefly evaluated for the stigmata of this complex. Lym-
phangioleiomyomatosis, another characteristic manifes-
tation of TSC, was identified in the lymph nodes of 3
(6.8%) of the 44 patients [33,41], 2 of whom had TSC.
The vast majority of the 44 patients received surgical man-
agement that included at least a hysterectomy.
The reported uterine PEComas have displayed a spectrum
of biologic behaviors, and any discussions about the
"prognosis" of PEComas as a single neoplasm is fraught
with the same fallacies of rendering a blanket statement
about the prognosis of a heterogeneous group such as
uterine smooth muscle tumors, for example. Follow-up
information and/or manifest malignancy at presentation
were available in 37 (84%) of the 44 patients. In a previ-
ous report [8], a subset of these cases (corpus only) was
classified into 2 groups based on patient outcome. The
first group was designated "malignant" and was com-
prised of cases associated with patient death of disease
and/or extrauterine extension at presentation. The second
group was designated "non-malignant" and was com-
prised of cases in which neither of the aforementioned
features was present [8]. After updating that paradigm
with cases reported since the report, 15 (44%) of the 34
corpus cases (with follow-up and/or manifest malignancy
at presentation) may be classified as malignant and the
remaining 19 (56%) as non-malignant. If the 3 cases pri-
mary in the cervix and with follow-up information are
included, there would be 16 (43%) of 37 cases in the
malignant group and 21 (57%) of 37 cases in the non-International Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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Table 1: Clinical features of the 44 reported cases of uterine PEComa***
REFERENCE Year Age (yrs) TSC Location Management Outcome
Hornick & Fletcher (39) 2008 34 NS Corpus NS NERM at 33 months
Armah & Parwani (40) 2008 59 No Corpus Hysterectomy/BSO performed 7-
years previously for presumed 
leiomyosarcoma; Renal and 
pulmonary metastases at current 
presentation; all resected
NERM at 15 months
Liang et al (41) 2008 59 Yes Corpus Hysterectomy/BSO/Pelvic and 
paraaortic Lymphadenenctomy, 
omentectomy, appendectomy, 
peritoneal biopsies; hormonal 
therapy
Extension into cervix at 
presentation; NERM at 10 months
Gan et al (20) 2007 40 NS Corpus Hysterectomy NERM at 16 months
33 NS Corpus Hysterectomy NERM at 32 months
44 NS Corpus Hysterectomy NERM at 52 months
Rammeh Rommani et al (21) 2006 35 No Corpus Excision NERM at 4 months
Azad et al (22) 2006 25 No Cervix Radical hysterectomy, 
Lymphadenectomy
Unavailable or Recent
Folpe et al (13) 2005 59 No Corpus Adjuvant Chemotherapy Liver and Lung metastases at 30 
months. Alive with metastases 30 
months
56 No Corpus Adjuvant Chemotherapy and 
radiotherapy
Lung and bone metastases at 11 
months; Alive with metastases 11 
months
36 No Corpus Hysterectomy, adjuvant 
chemotherapy
Lung metastases at 12 months, liver 
metastases 36 months; Death at 39 
months
42 No Corpus No additional surgery or adjuvant 
therapy
NERM at 11 months
28 No Cervix Hysterectomy and 
Lymphadenectomy
NERM at 36 months
48 No Cervix Adjuvant Radiotherapy NERM at 21 months
Jeon et al (23) 2005 9 No Corpus Neoadjuvant chemotherapy, 
Hysterectomy with 
Lymphadenectomy, Adjuvant 
Chemotherapy/Radiotherapy
Lymph node metastases at 
presentation, NERM at 18 months
Bernado Vega et al (27) 2005 34 No Corpus Hysterectomy/BSO Unavailable or Recent
Bosincu et al (24) 2005 59 No Corpus Hysterectomy/BSO, omentectomy, 
abdominal exploration
Pelvic recurrence at 6 months; 
Death at 12 months
48 No Corpus GnRH analogues, then 
Hysterectomy
NERM at 36 months
Fukunaga (25) 2005 40 No Corpus Hysterectomy/BSO, omentectomy, 
Adjuvant chemotherapy and 
radiation.
Ovarian and Omental metastases at 
presentation, Death at 16 months
30 No Corpus Hysterectomy NERM at 36 months
36 No Corpus Hysterectomy NERM at 6 months
Fukunaga (25,26) 2004 32 No Corpus Excision NERM at 12 months
Gao et al (28) 2004 60 No Corpus Hysterectomy/BSO, staging Unavailable or Recent
Darai et al (29) 2004 18 No Corpus Excision Pelvic recurrence and lymph node 
metastases, 6 months, NERM 
subsequent 24 months
Fadare et al (5) 2004 41 Yes Cervix Hysterectomy/BSO NERM at 35 months
Dimmler et al (32) 2003 61 NS Corpus Hysterectomy Lung metastases at 84 months
Greene et al (30) 2003 79 NS Corpus Hysterectomy/BSO Pelvic and abdominal recurrence at 
24 months; Death at 24+ months
Park et al (31) 2003 32 No Corpus Hysterectomy/RSO Right broad ligament/mesovarian 
extension at presentation; NERM at 
18 months
Vang & Kempson (33) 2002 40 No Corpus Excision Unavailable or Recent
54 No Corpus Hysterectomy/BSO Unavailable or Recent
56 No Corpus Hysterectomy/BSO Unavailable or Recent
75 No Corpus Hysterectomy/BSO, Adjuvant 
Radiotherapy
NERM at 31.2 monthsInternational Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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malignant group. There is no statistically significant differ-
ence in patient age between the 2 groups. The above anal-
ysis excludes the uterine case included in the series of Pan
et al due to lack of specific data [53].
Uterine PEComas: pathologic features
The uterine tumors reported as PEComas have been fun-
damentally characterized by a diffuse, nested and/or fas-
cicular proliferation of spindled and epithelioid cells that
display clear to eosinophilic cytoplasms, and which dis-
play immunoreactivity for melanocytic markers [5,13,19-
41]. A given lesion may be dominated by spindled cells or
epithelioid cells, but these cells are often admixed [8,13].
Some cases are comprised of cells with bland nuclei
whereas others display frank anaplasia; most fall some-
where within this spectrum. Multinucleated giant cells,
which appear to be degenerative in nature may also be
found [5,8,13,41] (Figure 1). The constituent cells may
display a perivascular distribution, but this feature is often
inconspicuous in the uterine cases [8]. PEComas typically
display a prominent network of small capillaries reminis-
cent of renal clear cell carcinoma or myxoid liposarcoma
(Figure 1). The tumors may be circumscribed with no or
minor areas of peripheral infiltration, or display a promi-
nent "tongue-like" infiltration into the myometrium
[8,33]. Two cases [5,41] were associated with clusters of
epithelioid cells outside of the main tumoral mass,
including the ovary and small bowel in one case [5]. This
phenomenon was designated "PEComatosis" in one 2004
report [5]. PEComas may display stromal hyalinization
that can be so diffuse as to obfuscate their underlying fea-
tures [19,25,33,35,39,41]. In addition to HMB-45, PECo-
mas also display immunoreactivity, albeit in lesser
proportions, to other melanocytic markers such as micro-
pthalmia transcription factor, Melan A, Mart-1, and
HMSA-1. Greater than 70% are positive for smooth mus-
cle actin (SMA), and almost half are positive for desmin
[8]. The full immunophenotype of uterine PEComas is
outlined in Table 2.
There have been three major attempts to correlate patho-
logic parameters of PEComas with patient outcome, in an
effort to enumerate morphologic criteria predictive of
malignant potential [5,8,13]. Folpe et al [13] derived their
proposed criteria from a review of PEComas reported
from a wide variety of anatomic locations. The resultant
A perivascular epithelioid cell tumor of the uterine cervix  that pursued a benign clinical course Figure 1
A perivascular epithelioid cell tumor of the uterine cervix 
that pursued a benign clinical course. Note the network of 
capillaries and the multinucleated giant cells. (from ref 5)
47 No Corpus Hysterectomy/BSO NERM at 1.5 months
49 Yes Corpus Hysterectomy/BSO NERM at 54 months
55 No Corpus Hysterectomy/BSO NERM at 2 months
58 No Corpus Hysterectomy/BSO Unavailable or Recent
Bonnetti et al (34) 2001 19 No Corpus Hysterectomy/BSO/pelvic and 
inguinal lymphadenectomy, Adjuvant 
chemotherapy and radiotherapy
Metastases to pelvic/inguinal nodes 
and vaginal extension at 
presentation. Local recurrence, 
bone and lung metastases 18 
months; no further follow-up
41 Yes Corpus Hysterectomy/BSO Ovarian metastases at presentation, 
NERM at 6 months
Michal & Zamecnik* (35) 2000 58 No Corpus Hysterectomy NERM at 48 months
48 No Corpus Hysterectomy NERM at 48 months
46 No Corpus Hysterectomy NERM at 12 months
46 No Corpus Hysterectomy NERM at 12 months
Ruco et al** (38) 1998 56 No Corpus NS Ovary and ileum metastases at 
presentation
Pea et al (19) 1996 57 No Corpus NS NERM at 24 months
TSC tuberous sclerosis complex; BSO bilateral salpingo-oophorectomy; NERM no evidence of tumor recurrence or metastases. *these authors 
[35] published a subsequent opinion in which they indicated that their cases are better designated epithelioid smooth muscle neoplasia [36].
**Presumes the same case is being described in references 37 and 38. ***Includes cases published in the English literature before 01/31/08 only, and 
excludes the case reported in reference 53 due to lack of data.
Table 1: Clinical features of the 44 reported cases of uterine PEComa*** (Continued)International Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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classification included 3 groups: 1) A "Benign" group in
which none of 22 cases displayed aggressive behavior and
which was characterized by tumor non-infiltrativeness,
tumor size less than 5 cm, non high nuclear grade, lack of
high cellularity, mitotic rate ≤ 1/50 high power fields
(HPF), no necrosis and no vascular invasion; 2) A "malig-
nant" group in which 12 (71%) of 17 cases displayed
aggressive behavior and which was characterized by
tumors grater than 5 cm, infiltrativeness, high nuclear
grade and cellularity, necrosis, lymphovascular invasion
and a mitotic rate ≥ 1/50 HPF; and 3)a group of tumors of
"uncertain malignant potential" that were characterized by
tumors with nuclear pleomorphism/multinucleated giant
cells [0 (0%) of 6 displaying aggressive behavior] or size
greater than 5 cm only [2 (12%) of 17 cases displaying
aggressive behavior] [13]. In our own aforementioned
analysis of 31 corpus cases which were classified based on
patient outcome into "Non-Malignant" and "Malignant"
groups, significant differences were found between these
2 groups regarding 3 pathologic parameters [8]. Regarding
tumor size, the malignant cases (average size 9.6 cm) were
significantly larger than their non-malignant counterparts
(average size 4.67 cm, p = 0.04). However, there were no
size thresholds that in of themselves could classify even
75% of the cases in both groups. The presence of coagulat-
ive necrosis (Figure 2) was highly associated with the
malignant group [present in 9 (82%) of 11 cases], as com-
pared with only 2 (11.8%) of the 17 cases in the non-
malignant group (p = 0.0002). Finally, a mitotic count of
≤ 1 mitotic figures/10 HPF was found in 16 (88%) of the
18 non-malignant cases but in only 4 (40%) of the 10
malignant cases (p = 0.01). Although the possibility of
suboptimal sampling remains, it is noteworthy that some
uterine PEComas have been reported in which metastases
developed in the absence of mitotic activity [23,29]. As
such, lack of mitotic figures may not be necessarily reas-
suring for non-malignancy. Application of the Folpe et al
[13] criteria to the uterine corpus cases showed that it clas-
sified 12 of the 13 malignant cases under our paradigm
[8] appropriately into a malignant group. The 13th case
[32] would probably be classified as being of uncertain
malignant potential. Because nuclear atypia and nuclear
pleomorphism were inconsistently defined in many of the
reported cases of uterine PEComa, The Folpe et al [13] cri-
teria would probably also classify most of our "non-
malignant" cases into their "uncertain malignant poten-
tial" group simply because of nuclear pleomorphism. Fur-
thermore, "infiltrativeness", which presumably
encompasses the "tongue-like" myometrial growth pat-
tern in some uterine PEComas, would remove a tumor
that otherwise qualifies from the "benign" group in the
Folpe et al [13] classification, which is at best questiona-
ble regarding correlation with outcome. None of the 3
cases with this infiltrative pattern (and follow-up) in the
series of Vang and Kempson [33], for example, recurred.
The case associated with intraabdominal PEComatosis
reported by Fadare et al [5] was otherwise histologically
benign and also did not recur.
As with conventional smooth muscle neoplasms of the
uterus, there are no morphologic criteria that can uni-
formly predict the malignant potential of all cases. None-
theless, the presence of coagulative necrosis and/or a
mitotic index >1 mitotic figure (MF)/10 HPF is highly
worrisome for malignancy and patients with such tumors
should be managed as such. However, a mitotic index >1
MF/10 HPF is typically seen in association with other fea-
tures such as necrosis and cytologic atypia. Cases that can
be classified as benign according to Folpe et al criteria [13]
should be reported as being highly unlikely to display
aggressive behavior based on limited evidence. In the
author's opinion, until more cases are described and prog-
nostic criteria become more finessed, all patients diag-
nosed with uterine PEComas should receive long-term
follow-up irrespective of the pathologic designation
because there is an inherent element of unpredictability to
these neoplasms.
Perivascular epithelioid cell tumors and some 
myomatous tumors of the uterus have 
overlapping clinicopathologic features
The principal controversial aspect of uterine PEComas
stems from the fact that they have a distinct clinicomor-
phologic and immunophenotypic overlap with some
smooth muscle neoplasms of the myometrium, which has
called into question the validity of their segregation as a
distinct clinicopathologic entity. In the simplest analysis
of the overlap, smooth muscle neoplasia may be viewed
as uterine tumors that always display myomatous differen-
Table 2: The immunophenotypic profile of the reported uterine 
PEComas**
Antibody Percentage positive
HMB-45 100
Smooth muscle actin 73
Vimentin 56
Desmin 49
Muscle-specific actin 36
CD10 25
Melan-A 24
CD117 9
CD34 5
Chromogranin 0
S100 3
Keratin 3
Epithelial Membrane Antigen 0
Inhibin 0
**Data from Fadare (8), and only includes markers for which at least 
10 cases have been tested. Any extent or intensity of staining 
considered positiveInternational Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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tiation and occasionally  display melanocytic differentia-
tion, whereas PEComas always  display melanocytic
differentiation and usually displays some myomatous dif-
ferentiation. From this construct, it becomes apparent
how controversies may arise regarding which end of this
putative spectrum is best considered a variant of the other
and which designation is most appropriate to apply for a
given case that falls within the areas of overlap. These
issues are discussed below.
Clinicomorphologic overlap
As noted previously, uterine PEComas are defined mor-
phologically by their constituent epithelioid and/or spin-
dle cells with eosinophilic to clear cytoplasm. However,
the uterine mesenchymal tumors that have traditionally
been diagnosed as epithelioid leiomyomas/leiomyosarco-
mas (and all their historic appellations: leiomyoblastoma,
clear cell leiomyoma/leiomyosarcoma, plexiform leiomy-
oma etc) are defined in a broadly similar fashion [54-61].
Epithelioid smooth muscle tumors of the uterus (ESM)
may grow in nests, cords or diffuse sheets. Their constitu-
ent cells should be predominantly epithelioid and typi-
cally display eosinophilic cytoplasm, although a clear
appearance may be seen in approximately 25% of cases
[54-57]. They generally do not display the vascular net-
work that is characteristic of PEComas. Stromal hyaliniza-
tion is a potential feature of both tumors and may be
extensive in both [8,55]. Both tumors may display multi-
nucleated giant cells [8,13,55]. Extracellular myxoid mate-
rial and osteoclast-like giant cells have been described in
rare cases of ESM [55].
The author examined historical data on the prognostic
clinicomorphologic features associated with those cases
reported as ESM to determine whether these are broadly
similar to those reported for uterine PEComas. First, cases
reported as uterine PEComas and ESM occurred in
patients in approximately the same age group (48 years
for ESM [54] and 45 years for PEComa, see above]. Sec-
ond, approximately 12–40% of cases reported as ESM
pursued a malignant clinical course as compared with 43–
44% of uterine PEComas (see above). However, the data
on ESM is based on series of consecutive cases [54-57],
whereas the data on PEComas is based on isolated case
reports and small series, which probably artificially
inflated the latter due to selection bias. Third, morpho-
logic criteria are significantly less predictive of biologic
behavior in ESM when compared with their conventional
(i.e. non-epithelioid) counterparts [17], which may theo-
retically be an indicator of a tumor group that is too
broadly defined. In their series of 26 ESM, Kurman and
Norris [54] found significant overlap regarding morpho-
logic features between malignant and benign cases. How-
ever, the presence of clear cells, stromal hyalinization, an
expansile tumoral margin and the absence of necrosis
were associated with benign behavior, whereas tumor size
6 cm or larger, extensive necrosis, infiltrating margins and
mitotic activity of ≥ 5 MF/10 HPF were more associated
with malignant behavior. The authors proposed the then
provisional criteria of ≥ 5 MF/10 HPF as the threshold that
defines malignancy. The Kempson group [57,61] found
that all cases with tumor necrosis behaved in a malignant
fashion, but that the absence of necrosis and cytologic aty-
pia did not guarantee a benign course if there is more than
5 MF/10 HPF. Seven cases in which there was no tumor
necrosis, no more than "minimal" atypia and <5 MF/10
HPF pursued a benign course. The authors recommended
that tumors with <5 MF/10 HPF, no necrosis, and moder-
ate to severe atypia be designated as being of "uncertain
malignant potential". Oliva et al [56] confirmed the
importance of mitotic activity: for uterus-confined cases, a
mitotic index of 2–4 MF/10 HPF was malignant in
approximately 50%. Prayson et al [55] did not find any
single morphologic criteria predictive of malignancy, but
the authors noted that their clinically malignant cases typ-
ically displayed tumor necrosis, cytologic atypia and
mitotic activity of at least 3–4 MF/10 HPF. All of these cri-
teria are applicable to cases reported as PEComas. Any
uterine PEComa with coagulative necrosis and/or a
mitotic index >5 MF/10 HPF will be classified as malig-
nant by either of the paradigms outlined above [8,13].
The mitotic index threshold that increases the probability
of aggressive behavior seems to be much lower for uterine
PEComas, however, the author is unaware of any uterine
PEComas in which increased mitotic activity is the only
worrisome feature (i.e. a tumor with greater than 1 MF/10
HPF unassociated with tumor necrosis and/or cytologic
This pathologically malignant PEComa was also clinically  malignant Figure 2
This pathologically malignant PEComa was also clinically 
malignant.International Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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atypia). Furthermore, as noted previously, at least 2 uter-
ine PEComas have pursued a malignant course in the
absence of any mitotic activity, although the level of sam-
pling in those cases is unclear [23,29].
Undoubtedly, some morphologic overlap exists between
cases reported as PEComas and those reported as ESM. To
summarize the above comparative data regarding clinico-
morphologic features, both tumors may display clear
cells, epithelioid cells, stromal hyalinization and multinu-
cleated giant cells. A delicate vascular network character-
izes PEComas but not ESM. Both are seen in patients in
the same age group. Both tumors can probably be classi-
fied as malignant if there is coagulative necrosis and/or >5
MF/10 HPF. The implications of mitotic activity below the
latter threshold seems to differ between both neoplasms,
although the data is limited.
Immunophenotypic overlap
Uterine PEComas definitionally display at least focal
immunoreactivity for melanocytic markers [8,10-15].
However, it appears that a substantial subset of uterine
smooth muscle tumors can also be positive for melano-
cytic markers [58,59,62-67]. Three studies [62-64],
although published only in abstract form, found at least
focal HMB-45 immunopositivity in 54 (65%) of 83 leio-
myomas. Furthermore, at least focal imunoreactivity for
melanocytic markers other than HMB-45 [Melan A and
miTF] were reported in 2 (22%) of 9 and 5 (100%) of 5
leiomyomas [64]. In contrast, the 16 leiomyomas tested
by Bosincu et al [24] were all HMB-45 negative. HMB-45
positivity has also been demonstrated in leiomyosarco-
mas [58,59,64-66]. Oliva et al [64] reported HM45 posi-
tivity in 21 (31%) of 67 leiomyosarcomas, with most
cases co-expressing Melan A. Simpson and Albores-Saave-
dra [65] recently confirmed those findings, reporting at
least focal HMB-45 positivity in 36% of conventional lei-
omyosarcomas. HMB-45 positivity was more frequently
found in poorly differentiated leiomyosarcomas as com-
pared with their well-differentiated counterparts [65].
Silva et al [58] found that HMB-45 positivity in ESM is
generally localized to the clear cell areas. The authors
selected 5 leiomyosarcomas with clear cell areas and at
least focal desmin/caldesmon positive spindle areas from
a group of 12 epithelioid leiomyosarcomas. Four (80%)
of the 5 cases were found to be HMB-45 positive only in
the clear cell areas. The 5th case had less than 1% clear cells
and was HMB-45 negative [58]. The latter findings were
confirmed by Hurrell and McCluggage [66] who found
that no immunoreactivity for HMB-45 in 3 epithelioid lei-
omyosarcomas without clear cell areas but clear cell-local-
ized HMB-45 positivity in 2 other epithelioid
leiomyosarcomas with clear cell areas. Five (56%) of 9
ESM were found to be HMB-45 positive in another study,
although the extent of cytoplasmic clarity in those cases
was not stated [64].
Because the normal myometrium may also be HMB-45
positive [62,63], and because the immunoreactivity has
been demonstrated for multiple melanocytic markers
(miTF, HMB-45 and Melan A), it is unlikely that this reac-
tion is merely artifactual. Melanocytic differentiation
appears to be an intrinsic biologic property of a subset of
smooth muscle tumors. It is noteworthy that HMB-45
positivity was only demonstrable in the metastatic deposit
of one case of uterine leiomyosarcoma [59], and that
HMB-45 positivity was associated with poor tumor differ-
entiation in a series of others [65]. As the author has noted
previously [6,8], there are established links between
melanocytic and smooth muscular differentiation in
other contexts. Among these is the expression of smooth
muscle actin in some cutaneous melanomas [68] and pig-
mentation in some myomatous tumors of the uterus [69].
Furthermore, cells derived from neural crest, the origin of
melanocytes, have been shown in animal model embryo-
logic studies to give rise to perivascular as well as
branchial smooth muscle cells [70,71]. Finally, in vitro
studies have also shown that neural crest cells have the
potential for differentiating into smooth muscle cells in
the presence of folic acid [72], transforming growth fac-
tor-beta [73] and some specific media [74].
To summarize the comparative data, approximately one-
third of conventional leiomyosarcomas may display at
least focal immunoreactivity for melanocytic markers,
and this should not alter their designation as leiomyosar-
comas. ESM may also be positive for HMB-45, predomi-
nantly in the clear cell areas, but probably also in the cells
with cytoplasmic eosinophilia. Keratin positivity may be
found in both ESM and uterine PEComas, but is signifi-
cantly more frequently positive in former than the latter
[8,75]. Desmin positivity is present in approximately 50%
of both ESM [76] and PEComas [8]. In analyses of a total
of 7 epithelioid leiomyosarcomas with clear cell areas,
smooth muscle actin was found to be diffusely positive in
6 and focally positive in 1 [58,66]. Smooth muscle actin is
positive in 80% of PEComas in general [13] and in 73%
of uterine PEComas [8]. As such, cases reported as ESM
and uterine PEComa display a substantial immunophe-
notypic overlap which, at minimum, is indicative of their
shared lines of differentiation. The few cases of ESM that
have been examined ultrastructurally have shown their
constituent cells to be comprised of numerous vacuolated
mitochondria [77], cytolysosomes and glycogen aggre-
gates [78]. Melanosomes were identified in one uterine
PEComa [31], but not in another [30].International Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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Uterine PEComas and epithelioid smooth 
muscle tumors: a practical approach
Given the aforementioned extent of clinicomorphologic
and immunophenotypic overlap that exists between uter-
ine PEComas and ESM (Table 3), and since 42 (95%) of
the 44 uterine PEComas were reported since the begin-
ning of 2000, the logical question arises as to whether
PEComas are a distinct clinicopathologic entity or
whether they merely represent a selected group of HMB-
45 positive smooth muscle tumors. In the author's opin-
ion, this is a false choice. First, the discussion has to be
"purified" by the stipulation that a uterine mesenchymal
tumor should not be designated a PEComa simply
because it is positive for HMB-45 or some other melano-
cytic marker. There is no significant debate at this junction
that conventional smooth muscle tumors (i.e. tumors that
are comprised predominantly of fascicles of spindle cells
with eosinophilic cytoplasm) can display immunoreactiv-
ity for melanocytic markers [64,65]. When this group of
tumors is removed the discussion can then be centered on
uterine mesenchymal tumors that are comprised predom-
inantly of epithelioid cells or an admixture of epithelioid
and spindle cells throughout the tumor.
A clinicopathologic entity should be pathologically (via
morphologic evaluation and/or ancillary techniques)
definable and have clinical significance. ESM have been so
classified for at least three decades. However, their behav-
ior has been notoriously difficult to predict from morpho-
logic criteria, which may be considered as evidence of
excessive heterogeneity in tumors currently defined as
ESM and the need to delineate biologically relevant sub-
sets within them. PEComas and ESM have significant sim-
ilarities but also significant differences (Table 3). Indeed,
an argument can be advanced that it is no more invalid a
position to consider PEComas as a variant of ESM than it
is to consider all previously reported ESM as variants of
PEComas. What is undisputable is that these tumors share
lines of differentiation. It is an impediment to scientific
progress when scientists take rigid, dogmatic positions
simply because of tradition. One approach to resolving
the PEComa versus ESM question is to postulate that a
given tumor is better characterized into a diagnostic cate-
gory if pathologically similar, extrauterine tumors are well
described. In this respect, it is noteworthy that epithelioid
smooth muscle tumors are decidedly rare outside of the
uterus. Most of the extrauterine (predominantly retroperi-
toneal and gastrointestinal) tumors that were previously
diagnosed as epithelioid smooth muscle tumors are now
considered epithelioid gastrointestinal stromal tumors. In
contrast, PEComas are considered anatomically ubiqui-
tous. One comparative genomic hybridization study
found a closer kinship, regarding the patterns of chromo-
some losses and gains, between a uterine PEComa and
extrauterine PEComas than between the uterine PEComa
and uterine smooth muscle neoplasia [53]. In animal
models carrying a germline mutation to the tuberous scle-
rosis 2 (TSC2) gene, there is an increased predisposition
to develop uterine and extrauterine tumors [79]. Notably,
a disproportionate percentage of the uterine tumors,
which the authors classified as leiomyomas/leiomyosar-
comas based on morphology and desmin/actin immuno-
reactivity, were of the epithelioid type. PEComas, of
course, have a known association with TSC2 gene altera-
tions [80]. Second, a recent study reported a 100% rate of
CD1a immunoexpression in PEComas from various sites
[81]. The author examined 5 ESM (4 epithelioid leiomyo-
mas and 1 epithelioid leiomyosarcoma) diagnosed by
WHO criteria [17] and all were negative for CD1a. (Fadare
O, unpublished data, 2008). Other selectively noteworthy
findings in uterine PEComas include their 9.1% associa-
tion with TSC, their occasional occurrence in young
patients [23,29,34], and their occasional display of metas-
tases in the absence of significant tumor mitotic activity
Table 3: A comparison of the clinicopathologic features of uterine PEComas and uterine epithelioid smooth muscle tumors.
Feature PEComa Epithelioid smooth muscle tumors References
Average patient age 45 years 48 years 54,
Epithelioid cells + + 8,54,55
Spindle cells + + 8,54,55
Multinucleated giant cells + + 5,8,13,41,55
Stromal Hyalinization + + 8,19,25,33,35, 39,41,54,55
Network of capillaries + - 8,13,54,55
Clear cells Usual Occasional 8,10–15, 54,55,58,66
Eosinophilic cells Usual Usual
Immunopositivity for at least one melanocytic marker 100% Up to 56% 8,10–15,64
Desmin immunopositivity 49% 50% 8,76
Smooth muscle actin immunopositivity 73% Up to 100% 8,58,66
Proportion of reported cases associated with TSC 9.1% No published data
see text; TSC tuberous sclerosis complexInternational Seminars in Surgical Oncology 2008, 5:7 http://www.issoonline.com/content/5/1/7
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[23,29]. Although the precise etiopathogenesis of PECo-
mas remain to be elucidated, the findings outlined above
argue for PEComas as a distinct entity or at least a specific
subset of smooth muscle neoplasia. The recent demon-
stration of elevated phospho-p70S6K and reduced phos-
pho-AKT expression, indicative of mTOR (mammalian
target of rapamycin) activation, in a group of extra-renal
PEComas raises the possibility of using mTOR inhibitors
such as rapamycin in the treatment of uterine PEComas
and is another argument for their routine segregation
[82].
The author shares the opinion that has been expressed by
others that most PEComas can be morphologically distin-
guished from classical epithelioid smooth muscle tumors
by their distinctive network of capillaries [13]. Nonethe-
less, these lesions may exist at different points on a single
clinicomorphologic spectrum [33], and their distinction
may admittedly be difficult. Future studies should evalu-
ate a series of archival epithelioid smooth muscle tumors
to determine whether cases that are morphologically and
immunophenotypically more consistent with PEComas
are identifiable, and perhaps more importantly, whether
these cases are prognostically distinct from the remaining
cases in the group. At present time, the author proposes
this practical approach to these neoplasms is as follows:
1) Predominantly conventional smooth muscle neo-
plasms that display immunoreactivity for one or more
melanocytic markers should be diagnosed as leiomyosar-
comas/leiomyomas, with a comment about their melano-
cytic differention. This is designed to segregate these cases
because the significance of melanocytic differentiation is
unknown, and melanocytic differentiation may emerge at
a metastatic site [59], with the attendant potential for the
misdiagnosis of the metastatic lesion as a primarily
melanocytic malignancy. The presence of clear or epithe-
lioid cells in an otherwise predominantly conventional
smooth muscle neoplasm should not affect its designa-
tion as such.
2) All epithelioid mesenchymal neoplasms of the uterus
should be tested for melanocytic markers, to include at
least HMB-45.
3) Tumors with absolutely characteristic morphologic and
immunophenotypic features are diagnosed as a perivascu-
lar epithelioid cell tumor (PEComa). However, given the
current state of evidence, it is no longer advisable to use
"PEComa" as a diagnostic term in isolation, as it is akin to
diagnosing a uterine mesenchymal tumor as a "smooth
muscle tumor" without further description. Rather, there
should be some statement regarding their expected bio-
logic behavior as predicted by morphologic characteris-
tics. PEComas should be described as being highly likely
to display aggressive behavior if they display coagulative
necrosis. A mitotic index of >1/10 HPF is highly worri-
some for malignancy but have been uniformly seen con-
current with other features such as cytologic atypia and
necrosis. PEComa cases that can be classified as benign
according to Folpe et al criteria [13] should be reported as
being highly unlikely to display aggressive behavior based
on limited evidence. All other cases (PEComas) are of
uncertain malignant potential. It is recommended that all
patients diagnosed with uterine PEComas receive long-
term follow-up irrespective of the pathologic designation
due to the unpredictability to these neoplasms.
4) Epithelioid mesenchymal tumors that do not display
all the characteristic features of PEComa should be diag-
nosed as epithelioid leiomyomas, epithelioid leiomyosa-
rcomas or epithelioid tumors of uncertain malignant
potential (if they otherwise have the features of these
lesions) per aforementioned criteria [17,54-57,61]. As
with their conventional counterparts, melanocytic differ-
entiation should similarly be noted if present.
5) Finally, as with all neoplasms, adequate sampling is of
paramount importance to ensure that all areas of these
uterine mesenchymal tumors are being optimally repre-
sented microscopically.
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